Article

The ADVANTAGE Seeding Trial: A Review of Internal Documents

Figure 3. Merck document tracking the average number of new prescriptions written by rheumatologists who were ADVANTAGE study group investigators.

Merck tracked new prescriptions written for both Vioxx and Celebrex (celecoxib; Pfizer, New York, New York) by ADVANTAGE investigators in the months after the trial. Investigators were given a portfolio profile grade of A+ to D on the basis of their prescription history of using Merck products. Arth CR = Arthritis Clinical Report no. 9907; AVG = average; Meded = medical education branch of the Institute for Internal Research; NRX = new prescriptions; RHU = rheumatologists.